(Q28221789)

1

0 references

I De Lepeleire

2

0 references

T M Crumley

3

0 references

F Liu

4

0 references

L A Wenning

5

0 references

N Michiels

6

0 references

E Vets

7

0 references

G O'Neill

8

0 references

J A Wagner

9

0 references

K Gottesdiener

Clinical Pharmacology & Therapeutics

10

0 references

language of work or name

English

0 references

publication date

June 2007

0 references

published in

0 references

volume

81

0 references

issue

6

0 references

page(s)

849-57

0 references

cites work

Costs and benefits of risk factor reduction for coronary heart disease: insights from screening and treatment of serum cholesterol

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100180

7 January 2021

High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease: assessing the data from Framingham to the Veterans Affairs High--Density Lipoprotein Intervention Trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100180

7 January 2021

High density lipoprotein cholesterol and mortality. The Framingham Heart Study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100180

7 January 2021

Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100180

7 January 2021

Benefits of niacin in patients with versus without the metabolic syndrome and healed myocardial infarction (from the Coronary Drug Project).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100180

7 January 2021

Efficacy and safety of an extended-release niacin (Niaspan): a long-term study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100180

7 January 2021

A new extended-release niacin (Niaspan): efficacy, tolerability, and safety in hypercholesterolemic patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100180

7 January 2021

Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100180

7 January 2021

Clinical trial experience with extended-release niacin (Niaspan): dose-escalation study.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100180

7 January 2021

Beneficial effects of rosuvastatin alone and in combination with extended-release niacin in patients with a combined hyperlipidemia and low high-density lipoprotein cholesterol levels

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100180

7 January 2021

Safety and effectiveness of Niaspan when added sequentially to a statin for treatment of dyslipidemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100180

7 January 2021

Treatment of hyperlipidemia with combined niacin-statin regimens

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100180

7 January 2021

A randomized trial of the effects of atorvastatin and niacin in patients with combined hyperlipidemia or isolated hypertriglyceridemia. Collaborative Atorvastatin Study Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100180

7 January 2021

Comparative efficacy and safety of pravastatin, nicotinic acid and the two combined in patients with hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100180

7 January 2021

Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100180

7 January 2021

Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100180

7 January 2021

Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with sta

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100180

7 January 2021

Niacin extended-release/lovastatin: combination therapy for lipid disorders

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100180

7 January 2021

New developments in the use of niacin for treatment of hyperlipidemia: new considerations in the use of an old drug.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100180

7 January 2021

Evaluation of effects of unmodified niacin on fasting and postprandial plasma lipids in normolipidemic men with hypoalphalipoproteinemia.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100180

7 January 2021

Niacin dosing: relationship to benefits and adverse effects

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100180

7 January 2021

The safety of over-the-counter niacin. A randomized placebo-controlled trial [ISRCTN18054903]

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100180

7 January 2021

Prolonged-release nicotinic acid: a review of its use in the treatment of dyslipidaemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100180

7 January 2021

Niacin for dyslipidemia: considerations in product selection.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100180

7 January 2021

New perspectives on the use of niacin in the treatment of lipid disorders

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100180

7 January 2021

Effect of two aspirin pretreatment regimens on niacin-induced cutaneous reactions

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100180

7 January 2021

Aspirin blocks nicotinic acid-induced flushing

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100180

7 January 2021

Low-Dose Aspirin and Ibuprofen Reduce the Cutaneous Reactions Following Niacin Administration

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100180

7 January 2021

Influence of Indomethacin on Flush Induced by Nicotinic Acid in Man

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100180

7 January 2021

Is cutaneous flushing prostaglandin mediated?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100180

7 January 2021

GPR109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushing

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100180

7 January 2021

Effects of intravenous infusions of prostaglandin D2 in man

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100180

7 January 2021

Release of markedly increased quantities of prostaglandin D2 in vivo in humans following the administration of nicotinic acid

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100180

7 January 2021

Tolerance to nicotinic acid flushing

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100180

7 January 2021

Identification of skin as a major site of prostaglandin D2 release following oral administration of niacin in humans

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100180

7 January 2021

Prostaglandin D2 is a potent chemoattractant for human eosinophils that acts via a novel DP receptor

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100180

7 January 2021

Prostaglandin D2 selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100180

7 January 2021

Molecular characterization of a mouse prostaglandin D receptor and functional expression of the cloned gene

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100180

7 January 2021

Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100180

7 January 2021

Clinical update on the use of niacin for the treatment of dyslipidemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100180

7 January 2021

Guidelines for visualization of cutaneous blood flow by laser Doppler perfusion imaging. A report from the Standardization Group of the European Society of Contact Dermatitis based upon the HIRELADO European community project

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100180

7 January 2021